2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2/3
1
Status
Withdrawn
1
Terminated
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
2
Endocrine
2
Conditions
Thyroid Neoplasms
2
Thyroid Carcinoma, Anaplastic
2
Head and Neck Neoplasms
1
Interventions
Iodine-131
21
lenvatinib
17
Magnetic Resonance Spectroscopy
17
trametinib
13
Sorafenib
13
Thyrotropin Alfa
12
pembrolizumab
11
dabrafenib
11
Thyroidectomy
10
Surgical Procedures, Operative
10
Thyroxine
9
Paclitaxel
9
vandetanib
8
selpercatinib
8
Sunitinib
7
Nivolumab
7
Fluorodeoxyglucose F18
7
cabozantinib
6
anlotinib
6
Everolimus
6
Biopsy
6
pazopanib
5
Vemurafenib
5
Triiodothyronine
5
Specimen Handling
5
Saline Solution
5
Radiotherapy
5
Radiofrequency Ablation
5
Iodine-124
5
Cyclophosphamide
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Thyroid Neoplasms
×
combretastatin
×
Clear all
NCT00507429
2014-06-09
FACT
Mateon Therapeutics
Phase 2/3
Terminated
80 enrolled
10 charts
NCT01701349
2014-05-01
FACT2
Mateon Therapeutics
Phase 3
Withdrawn